Dr. Mahadevan is a Professor of Medicine and a recognized expert and highly experienced Physician-Scientist in Hematology and Oncology, and currently the Director of Phase I clinical trials and Co-Director of Experimental Therapeutics at the University of Arizona – Arizona Cancer Center. He received his medical degree from the University of London, England, UK. He is certified by the American Board of Internal Medicine, subspecialty of Medical Oncology.
Dr. Mahadevan’s major area of clinical interest is in the treatment and management of patients with Pancreatic cancer, Gastrointestinal Stromal Tumors (GIST), Myelodysplastic Syndromes (MDS) and non-Hodgkin’s lymphoma (NHL) including Chronic Lymphocytic Leukemia (CLL).
As Director of the Phase I Program, he conducts first-in-human clinical trials with new drugs for patients with all solid tumor types as well patients with MDS, CLL and NHL. His research interest focuses on discovering novel therapeutic targets through a rigorous validation process and then design drugs to these targets using a structure-based drug discovery algorithm.
Dr. Mahadevan’s expertise in the above tumor types is that he conducts both Phase I and II first-in-human therapeutic trials in patients who have failed front line therapies. The Phase I Drug Development Program includes Dr. Mahadevan as team director, a nurse practitioner, a program manager, two senior research nurses, two clinical research coordinators and a pharmakokinetics lab specialist.
Multiple new drugs are available for patients with both solid and hematologic malignancies. Clinical research interests are to develop the drug alone and in combination for novel Phase I combination studies to enhance survival. Laboratory interests are focused on understanding resistance mechanisms in Pancreas Cancer, GIST, CLL and NHL.
Dr. Mahadevan's laboratory expertise is to discover novel therapeutic targets by a rigorous validation process and then design drugs to these targets using a structure-based drug discovery algorithm. To this end he has been successful in taking a small molecular inhibitor to c-Kit/PDGFR all the way from the bench to the clinic. MP470 (Amuvatinib) a c-Kit/PDGFR tyrosine kinase inhibitor is now in Phase I clinical trials.
Since the University of Arizona Cancer Center received the prestigious Lymphoma SPORE grant in 2008 from the NCI/NIH to evaluate drugs targeting Aurora Kinases in NHL, major strides have been made in treating both B- and T-cell NHL patients where significant clinical activity has been observed. Currently, novel combination therapies for NHL are in the process of being developed for future clinical trials.
Other areas of translation research include identifying novel cell surface therapuetic targets in pancreatic cancer and new drugs and combinations for gleevec and sutent resistant GIST. For pancreas cancer the translational component involves the design and humanization of murine antibodies as a therapeutic as well as elucidating the mechanism of action of the therapeutic antibody. Pre-clinical research involves in vivo and mouse pancreatic cancer models to demonstrate safety and efficacy of the therapeutic. For GIST, CLL and NHL novel drug combinations are being evaluated for future clinical trials.
Dr. Mahadevan has a demonstrated track record of delivering first-in-human investigational agents for all oncology therapeutics. In addition, he has successfully directed a structure-based translational drug discovery laboratory program with the award of 6 US patents for new drugs targeting novel driver oncogenes. As PI or Co-PI on several NIH and Foundation grants, he established proof-of-concept and delivered on drug discovery - R01 (AKT PH domain inhibitors) and on drug development - NSF (Prostate cancer translational drug development), SPORE in Lymphoma (Aurora kinase inhibitor therapy for aggressive lymphoma) and SWOG Hope Foundation (targeted therapeutics for aggressive B-cell non-Hodgkin Lymphomas). The CCSG leadership opportunity provided transformational change, utilizing his expertise to create tangible and measurable improvements to enhance research value, build a sustainable New Therapeutics program to optimally deliver patient care and a translational drug discovery platform to dismantle resistance to targeted therapies.
Dr. Mahadevan has recently taken the position of Co-Leader of the Therapeutic Development Program at the University of Arizona Cancer Center.
2000-2002 AMGEN Fellow of the Year Award
Arizona Cancer Center
9/91–10/94 Fogarty International Fellowship
Laboratory of Cellular and Molecular Biology
National Cancer Institute
National Institutes of Health
1998–1990 Dane Foundation Fellowship
British Medical Council
British Medical Association
BMA House, England
US Patent #920214.00004 Inhibitors of C-Kit and PDGF Receptor Tyrosine Kinases
US Patent #920214.00003 Aurora 2 Kinase Inhibitors
US Patent #263922US-2204-2204-96 Anti-CEACAM6 antibodies for the treatment of cancer
US Patent #7,326,713 Substituted Tricyclic Compound as Protein Kinase Inhibitors
US Patent #7,326,712 Substituted Tricyclic Compound as Protein Kinase Inhibitors
US Patent #7,335,662 Substituted Tricyclic Compound as Protein Kinase Inhibitors
2002 American Association for Cancer Research (AACR) – Active member
2002 American Society of Oncology (ASCO) – Active- Junior Member
2003 Current Medicinal Chemistry–Editorial Board (Anti-Cancer Drug Design)
2004 Supergen Pharmaceuticals, Inc. – Scientific Advisor
2005 American Society of Hematology (ASH) – Active Member, Abstract Reviewer (2007)
2003 Diplomate, American Board of Medical Oncology